Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin [August 2014]

Product Code:
596200299
Release Date:
August 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Breast Cancer: ALTTO, ExteNET, BOLERO-2, PALOMA-1 trials, GlaxoSmithKline’s Tykerb, Novartis’ Afinitor, Pfizer, Puma’s neratinib, Pfizer’s palbociclib.

Highlights from this event update bulletin

  • PALOMA-1: data alone are unlikely to garner approval, but optimism for Pfizer’s palbociclib remains
  • ExteNET: will disease-free survival translate to overall survival for Pfizer and Puma’s neratinib?
  • Neratinib’s tolerability profile will likely limit its use in the adjuvant setting
  • ALTTO: use of GSK’s Tykerb in the adjuvant setting unlikely due to disease-free survival results
  • ALTTO and NeoALTTO: results cast doubt on the use of pCR as surrogate measure of efficacy
  • BOLERO-2: mixed opinions about Novartis’ Afinitor and the significance of overall survival results

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved